The document summarizes a panel discussion event on personalized medicine hosted by the HBA Metro Affinity Group and Women In Science. It provides details on the event agenda, location, speakers, and topics. The event will bring together experts from Bristol-Myers Squibb, Coriell Institute, and Genomic Expression to discuss obstacles and opportunities in personalized medicine from research to clinical use. The panel will provide insights on how personalized medicine can transform the pharmaceutical industry.

1. Women In Science
HBA Metro Affinity Group
Personalized Medicine: Is It Our Future?
December 12, 2012
5:30-6:00 pm
Registration/Networking &
Light Dinner
6:00-6:20 pm
Welcome/Opening Remarks -
Natalie Lotier, Vice President,
BMS ; Dr. Brian Daniels, Senior
Vice President BMS ; Terry Beebe
Thomas, HBA Metro Chapter
President ; Dr. Deshanie Rai, WIS
Event Co-lead
6:20-8:00 pm
Panel Discussion / Q&A - Dr.
Steven Averbuch, David
Avitabile, Dr. Albert Giovenella,
Erynn Gordon, & Gitte Pedersen
8:00-8:30 pm
Closing Remarks &
Networking - Dr. Sharon
Henry, Vice President BMS &
Alane Taratuska, WIS Event Co-
Lead
Location
Bristol-Myers Squibb
777 Scudders Mill Road
Building No. 2
Plainsboro, NJ 08540
609-897-2000
Welcome to HBA Metro Chapter’s first person-
alized medicine (PM) event that will encompass
presentations and discussions on the actions
and initiatives being undertaken by the NIH,
FDA and private companies in response to the
revolution in genomics technology. This event
will bring together an interdisciplinary group of
experts to provide insights into how PM can
transform the pharmaceutical industry. Audi-
ence members will gain knowledge on what
obstacles and opportunities will need to be
addressed to make PM a new paradigm in the
treatment of patients from the research labora-
tory, to the clinic and doctor's office, as well as
to in-home use. Following the panel discussion,
there will be an extended networking session
for you to build relationships with other health-
care professionals.
Steven Averbuch, M.D.
Vice President, Early Global Clinical
Research Oncology and Head,
Pharmacodiagnostics, Bristol-Myers
David Avitabile
President, JFK Communications &
CEO BioCore Medical Communications
Albert J. Giovenella, Ph.D.
Adjunct Assistant Professor of
Medicine, Perelman School of Medicine
at the University of Pennsylvania
Erynn Gordon, M.S.
Director of Genetic Counseling,
Coriell Institute for Medical Research
Gitte Pedersen
CEO & Founder, Genomic Expression

2. Corporate Sponsor Team
Brian Daniels, M.D.
Senior Vice President, Global Development &
Medical Affairs
Opening Remarks
VP, Global Product Strategy & Global Manufac-
turing & Supply Strategy, Bristol-Myers Squibb
Natalie is currently a VP in Global Supply Chain at Bristol-
Myers Squibb based in New Brunswick. In her dual role,
Natalie is responsible for the GMS Strategy office de-
signed to support the GMS vision of becoming the indus-
try’s benchmark manufacturing and supply. In addition,
she has both Global Supply Chain strategic & operational
accountability for developing and implementing the GMS
aspects of Product Lifecycle Management for global key &
growth products including New Product
Launches. Natalie joined BMS in 2009 as VP, Americas
Supply Chain and Logistics. Prior to joining BMS, Natalie
had an extensive career with Merck & Co. with senior
roles in Supply Chain, Procurement & IT.
Natalie holds a BS & MBA from Rutgers University &
currently serves on the Executive Advisory Board for the
HBA Metro Chapter.
Natalie Gerdt Lotier, MBA
VP, Global Medical- Cardiovasculars and Me-
tabolics , Bristol-Myers Squibb
Dr. Henry is VP, Global Medical- Cardiovasculars and
Metabolics, supporting co-development and execution of
global medical and life cycle management objectives. She
directs a headquarters medical organization, responsible
for disease strategy leadership teams for Europe, Asia
Pacific and Intercon. Her career began in BMS as Assis-
tant Director of Clinical R&D, and spans a variety of clini-
cal and medical experiences including medical strategy,
medical affairs, and patient advocacy /health affairs.
Under her leadership several innovative medical func-
tions evolved within BMS - she led the integration and
development of the first field-based medical organization
following the 1991 merger of ER Squibb and Bristol
Myers. As VP, Health Care Management, she led design
and development of disease management services and as
VP, Health Care Science and Technology, she created
a novel web casting capability, receiving several BMS
recognition Awards. She has held board positions at the
regional & local level of the American Heart Association,
was elected to the 2012 HBA corporate board of direc-
tors, and is an Executive Sponsor for the BMS Women In
Science (WIS) leadership development organization .She
has also been recognized with several community leader-
ship awards, including the first Women’s Leadership
Award from Health Watch, a non-profit Health Informa-
tion organization focused on minority health and fea-
tured in Ebony Magazine as one of the 100 Most Promis-
ing Black Women in Corporate America.
Sharon Henry, M.D.
Brian Daniels, M.D., is Senior Vice President, Global Development and Medical Affairs, and
a member of the Senior Management Team, the company’s most senior leadership group.
He has responsibility for developing innovative medicines that meaningfully improve the
standard of care for patients and communicating the value of these medicines to society to
ensure their safe and appropriate use.
Brian joined Bristol-Myers Squibb in 2000 as Vice President of the Immunology, Pulmo-
nary, and Der-matology therapeutic area, where he provided strategic oversight and led
the early development of compounds including Orencia and belatacept. In 2002, he was
promoted to Vice President, Full Development, providing leadership to the development of
six key clinical programs including Reyataz and Baraclude. Brian also led efforts to im-
prove productivity and to standardize and integrate the global execution of clinical trials
as Vice President of Global Development Operations.
Brian is involved in a variety of activities at Bristol-Myers Squibb. Of particular impor-
tance, Brian is the Executive Sponsor of the Business Women’s Affinity Group. Brian is also
a strong supporter of the BMS Women in Science global network.
Prior to joining Bristol-Myers Squibb, Brian spent four years at Merck Research Laborato-
ries in clinical research where he ultimately assumed the role of senior director, Pulmo-
nary and Immunology. He has also worked in clinical research at Genentech.
Brian received his M.D. from Washington University School of Medicine and completed
residencies in Internal Medicine at New York Hospital and Rheumatology at the University
of California in San Francisco. He also received bachelor and master degrees in biology
from MIT.

3. Steven D. Averbuch, M.D.
Dr. Averbuch is currently Vice President, Early
Global Clinical Research Oncology and Head,
Pharmacodiagnostics, Bristol-Myers Squibb
Company based in Lawrenceville, NJ, USA. Since
joining BMS, Dr. Averbuch has led the strategic
direction for the exploratory oncology pipeline
through the execution of Phase 2. He is respon-
sible for the oncology clinical research contribu-
tions to business development and he has par-
ticipated in 7 successful transactions. In 2008,
Dr. Averbuch founded and established the Phar-
macodiagnostic Team, the precursor to the
Pharmacodiagnostic Center of Excellence
(CPDx) of which he is the current Head. The
CPDx is a multidisciplinary team of subject
matter experts responsible for the development
and commercialization of companion diagnos-
tics for BMS products across all therapeutic
areas. Currently, Dr. Averbuch is responsible for
leading an organizational change management
initiative to enable translational research and
development across R&D. Dr. Averbuch previ-
ously held positions at Merck Research Labora-
tories, AstraZeneca, and Mount Sinai School of
Medicine. He received his M.D. and Internal
Medicine training from the University of Illinois,
Chicago and his Medical Oncology training at the
National Cancer Institute, Bethesda, Maryland.
Dr. Averbuch has authored over 60 peer re-
viewed publications and book chapters and he is
a co-author on one patent. He is currently on
the Advisory Board for the University of Kansas
Institute for Advancing Medical Innovation. He
is a member of the American Society of Clinical
Oncology and the American Association for
Cancer Research having served on multiple
committees for both organizations.
David Avitabile has more than 20 years of ex-
perience in healthcare communications and
more than 10 years public relations experience
in both the US and Europe. Prior to joining JFK
Communications as a partner, David was SVP,
Global Strategic Development for AXIS Health-
care Communications, a holding company con-
sisting of 8 diversified healthcare communica-
tions companies providing lifecycle manage-
ment services to the global pharmaceutical-
biotech industry. At AXIS, David was responsible
for developing key client relationships world-
wide and worked with the presidents of AXIS
companies to identify and pursue new business.
Prior to joining AXIS, David established the
London office of ApotheCom, a global medical
communications company and the largest mem-
ber of the AXIS family of companies. As Manag-
ing Director of ApotheCom Europe, David was
responsible for business development and
creating a senior team at ApotheCom Europe.
David has also held positions as Director of
Business Development and Client Services
Director at OCC Europe, headquarters of a global
medical communications company with offices
in Europe, the United States, Japan and Austra-
lia. Here David was responsible for global busi-
ness development and overseeing a client ser-
vices team managing global medical communi-
cations programs for clients including J&J, Astra-
Zeneca, Pharmacia and Shire Pharmaceuticals.
At interSCIENCE, a global healthcare communi-
cations agency, David was responsible for build-
ing and managing a highly successful client
services team in the London office, developing
and implementing international programs for
clients including Sanofi, Merck (MSD), and As-
traZeneca. David has deep therapeutic area
experience including oncology, cardiovascular,
immunology, GI and CNS. He has launched sev-
eral new compounds and has contributed to
global product communications and commer-
cialization teams for clients. David has worked
at and managed both small agencies and large.
His experience includes account management
roles at New York – based agencies Medicus
Intercon and Nelson Communications, as well as
smaller, boutique healthcare PR agencies such
as Van Vechten & Associates and Mammoth
Communications.
Dr. Albert J. Giovenella spent 26 years in The
Pharmaceutical Industry in numerous phases of
Drug Research and Market Support. At Smith-
KlineBeecham from 1982-1985, he supervised
the In-vitro Antibiotic Discovery Laboratory. In
1986-1988, Dr. Giovenella worked as a Clinical
Studies Manager, designing and analyzing Phase
IV Studies in Microbiology, Anti-emetics, and
Gastroenterology, and as Consultant to the
World-wide Vice President of R&D at SKB. At the
same time, he completed his Doctoral Studies at
the University of Pennsylvania, studying In-
formed Consent, and the Educational Back-
grounds of Members of Institutional Review
Boards. For the next 20 years (1988-2008), he
moved to Merck and Co., Inc. as Health Science
Consultant in Gastroenterology and Metabolic
Bone Diseases. At this time, he published his
most recent three articles on Autonomy, on
Partnering in Pharmaceutical Education, and on
Clinical Internships, while organizing two Na-
tional Meetings on Education in Metabolic Bone
Diseases. While at Merck, from 1988-1994, Dr.
Giovenella was Adjunct Instructor in the Gradu-
ate School of Education, teaching Ethical Issues
in Health Professions Education to Graduate
Students in that Department. In 1996, he
founded the Pennsylvania Osteoporosis Society,
the Delaware Falls Prevention Group, and
started five Working Groups in various thera-
peutic areas. In March of 2008, Dr. Giovenella
retired from Merck, and joined the University of
Pennsylvania as an Adjunct Assistant Professor
of Medicine in Geriatrics to study the relation-
ship between Industry and Academic Medicine,
as well as Drug Development Affecting Aging
Populations Internationally. He tracks basic
science and mechanism of action discoveries
and development on a daily basis, and intro-
duces these new medicine concepts to Geriat-
rics. Dr. Giovenella is a Fellow of the University
of Pennsylvania Institute on Aging. He holds
memberships in the Pharmaceutical Consultant
Consortium and Pennsylvania Bio. He currently
teaches courses, networks with start-up compa-
nies, and studies Drug Development Trends and
Success Rates.
Erynn S. Gordon is director of genetic counseling
at Coriell Institute, with a focus on the Coriell
Personalized Medicine Collaborative (CPMC), a
research study that aims to evaluate the utility
of using the knowledge of genetics in medicine.
Erynn leads research on the psychosocial and
behavioral impact of personalized medicine,
provides genetic counseling services to CPMC
participants, and develops educational re-
sources, relevant to the CPMC, for healthcare
providers and the public. An active member of
the genetic counseling community, Erynn has
served in numerous leadership positions, in-
cluding President of the American Board of
Genetic Counseling (ABGC) (2012), chair of the
Certification Examination Committee, a commit-
tee of the ABGC charged with creating and ad-
ministering the national certification examina-
tion for genetic counselors and Chair of the
Ethics Subcommittee of the National Society of
Genetic Counselors from 2004-2005. In addi-
tion, Erynn currently sits on the Governor’s
Advisory Council on Genetic Counseling for the
State of New Jersey. Prior to joining Coriell,
Erynn conducted research on the impact of non-
disease genetic testing on self-concept and
provided genetic counseling to patients in the
Muscular Dystrophy Association clinic and the
neurogenetics clinic at the Research Center for
Genetic Medicine at Children’s National Medical
Center in Washington, DC. From there, Erynn
moved to the University of Maryland School of
Medicine and contributed to research studies on
Huntington’s disease and Tay Sachs disease and
provided genetic counseling services to the
hereditary cancer clinic, the Huntington’s dis-
ease clinic, and the adult genetics clinic. Erynn is
a board-certified genetic counselor who re-
ceived her undergraduate degree in psychology
and biology from Lehigh University, and her
master’s degree in genetic counseling from the
University of Pittsburgh School of Public Health.
David Avitabile Erynn S. Gordon, M.S. Gitte Pedersen
Gitte L. Pedersen has more than 20 years of
management experience in the biotech and
pharma industry. She has held a number of
executive positions at NovoZymes, where she
successfully developed and launched new prod-
ucts worldwide. In 1997 she established an
advisory firm, Proximity Ventures, and in that
capacity, she has advised a number of biotech
and government institutions resulting in numer-
ous licensing and equity deals with companies
such as GSK, JnJ, Merck, P&G, Wyeth, and Ta-
keda. Her aggregated deal resume is more than
$1 billion. Gitte Pedersen is the co-founder of
Genomic Expression and has served as its CEO
since 2009. Gitte has a masters in chemical
engineering and a business degree. Genomic
Expression’s hypothesis-free biomarker-
discovery platform uses intelligent target-
filtering technology integrated with sequencing
short reads on a small chip addressing the sam-
ple prep and data analysis bottlenecks in cur-
rent sequencing platforms. Prior to the wet lab,
we use bioinformatics to optimize our applica-
tions using existing sequence data. Then we
deploy an intelligent target-filtering process,
which generates a single-stranded tag library.
Because the tags are single stranded, it is possi-
ble to detect all possible tags using a universal
high-throughput platform. The cost per sample
is low, the content/test very high and hypothe-
ses free. Our approach represents a paradigm
shift in the biomarker-discovery process, saving
up to $20 million and more than two years in
pre-clinic testing while increasing the probabil-
ity of success. We are developing genomic signa-
tures that translate into, for a doctor, easy-to-
understand information regarding treatment
options for cancer patients, supported by a $30
million grant project where we have access to
15 million biological samples associated with
cradle-to-grave electronic medical records. We
partner with pharma and diagnostic companies
to provide access to the platform in a service
and solution model.
Albert J. Giovenella, Ph.D.
Panelists

4. Women In Science
Jean Hom Chow, M.Sc., M.D.
Chair
Medical Director, Worldwide Regulatory
& Safety, Pfizer Medical Division,
Pfizer, Inc.
Jean works in New York for Pfizer’s Worldwide
Regulatory and Safety, a division dedicated to
ensuring regulatory compliance and pharma-
covigilance to advance the health of patients
receiving our products. Previously, Jean held a
variety of leadership roles within Pfizer; her
areas of medical experience span anti-infectives,
immunology and vaccines, allergy and respira-
tory, psychiatry and mental health, urology and
sexual health, neurosciences, cardiovascular, and
established products. Jean’s medical background
includes pediatrics and infectious diseases. She
holds a Bachelors degree from the Sophie Davis
School of Biomedical Education at The City Col-
lege of New York and an M.D. from the Mount
Sinai School of Medicine. She also holds a Mas-
ters degree in Pharmaceutical Sciences from the
Hibernia College of Dublin, Ireland. Jean also
participated in the 2009 HBA Metro Chapter
Group Mentoring Program as a Mentor.
Senior Scientific Leader, DSM
Deshanie Rai works as a Senior Scientific Leader
at DSM, a Life and Material Sciences based com-
pany. Specifically, her role is that of a transla-
tional scientist within the Human Health and
Nutrition group. She also serves as an Adjunct
Assistant Professor at the University of Illinois,
Urbana-Champaign (UIUC). She has a solid back-
ground in the area of nutrition, immunology and
endocrinology. Her post-doctoral training was
in the area of Molecular Biology and Endocrinol-
ogy. She has been the recipient of many scholar-
ships and awards and has been an invited
speaker at national and international meetings.
Deshanie continues to publish in peer-reviewed
scientific journals, and has several patents. De-
shanie is excited to be a member of the H.B.A.’s
“Women in Science” committee and is enjoying
working with her team in the planning and im-
plementation of events to help promote science
in general, and more specifically, to help advance
women in science.
Deshanie Rai, M.Sc., Ph.D.
Event Co-Lead
Alane Taratuska, M.Sc.
Event Co-Lead
Visiting Scientist, Harvard Medical
School, Translational Research. Clinical
Diagnostics: Diabetes
Alane is a neuroscientist working in the biotech-
nology sector in regenerative medicine & pres-
ently, diagnostics. Her preclinical work on neu-
rodegenerative disease and cell therapeutics has
been presented at major conferences, & her
clinical research included the development of a
clinical assessment tool for monitoring the effi-
cacy of medications in the treatment of trau-
matic brain injury. Her work as a project man-
ager & team leader in cell engineering is culmi-
nating in two patent applications. Being in the
start-up environment has allowed her the oppor-
tunity to participate in developing business
strategies and corporate infrastructure & act as
scientific liaison for external collaborations. She
has a passion for mentoring & teaching, & is a
community volunteer. Her hobbies are Fla-
menco, fitness, & classical guitar.
Senior Research Scientist
Florence is a Senior Research Scientist with
expertise in Oncology. She obtained her Ph.D. in
Cellular Biology from University XI of Paris,
France where she investigated the effect of ultra-
violet radiation on skin cancers. She then held a
post-doctoral position at the Friedrich Miescher
Institute, a biomedical research institute part of
Novartis Research Foundation, in Basel, Switzer-
land. There, she worked as a team leader and
project manager on biomarker validation and
therapeutic target identification. Florence is the
author of 2 patents and many peer-reviewed
publications. Her goal is to work at the interface
between basic research and clinical science.
Florence is a founder member of “Granite”, a
community association to restore an old farm-
house in France.
Florence Brellier Ph.D.
Committee Member

5. Women In Science
Senior Scientist, Product & Pipeline
Scientific Support, Boehringer
Ingelheim Pharmaceuticals
Ashley works in the cardiometabolic disease re-
search group in R&D at BI. Her primary responsi-
bility encompasses preclinical support for the
new oral anticoagulant drug Pradaxa®. In her
role, Ashley liaises across several functions in-
cluding medical affairs, marketing, legal, and pro-
ject management to develop, align, and deliver
data packages supporting Pradaxa. Ashley also
initiates and supports external collaborations
with global partners in academic centers and
biotech companies. Ashley is thrilled to be in a
position which utilizes her preclinical knowledge
and skills across several disciplines and enables
interaction with partners along the spectrum of
drug discovery to support the life cycle manage-
ment of a licensed drug. Prior to joining BI, Ashley
worked as a post-doctoral fellow at the UPenn
School of Medicine where she also received her
Ph.D. in the genetics and cell and molecular biol-
ogy of cardiopulmonary development and dis-
ease.
Ashley Goss, Ph.D.
Committee Member
Formulation Lead (Pharmaceutical Devel-
opment), Inhalation Center of Excellence,
Merck & Co., Inc. , Merck
As a Formulation Lead at Merck, Keat Theng’s pri-
mary responsibility is to lead the formulation and
process development activities for inhalation prod-
ucts commercialization. She pursued her postdoc-
toral fellowship at The University of Texas at Austin,
working on particle engineering for solubility and
bioavailability enhancement of poorly soluble
drugs. Prior to joining Merck, she was a Scientist at
the Institute of Chemical and Engineering Sciences,
A*Star, Singapore, leading projects in novel formula-
tion approaches for a consumer care product and
scale-up manufacturing of a coating chemical. Keat
Theng has a breadth of formulation development
experience for pharmaceutical and consumer prod-
ucts, encompassing inhalation, oral, dermatological
and hair care products. She obtained her PhD
(Pharmaceutics) and BSc (Pharmacy) from National
University of Singapore and was a recipient of the
A*Star Graduate Scholarship in Singapore.
Keat Theng Chow, Ph.D.
Committee Member
Research Scientist, Assay Development,
Intra-Cellular Therapies, Inc.
Jennifer works as a research scientist in the
Department of Assay Development at Intra-
Cellular Therapies, Inc., an early stage pharma-
ceutical company developing novel treatments
for diseases of the central nervous system. She
graduated from Cornell University with a BSc in
Biology and earned her PhD in Molecular and
Cellular Neuroscience from Colorado State Uni-
versity. Following a postdoctoral fellowship in
the Department of Pharmacology at the Univer-
sity of Washington, Seattle, she joined Intra-
Cellular Therapies to develop assays using her
expertise in ion channels and electrophysiology.
Since, she has expanded her work into cell biol-
ogy, working across departments to study the
effects of compounds on neuronal signaling
pathways.
Jennifer O’Brien, Ph.D.
Committee Member
Director, Epidemiology, Worldwide
Safety Strategy, Pfizer, Inc.
Lisa is an epidemiologist within Worldwide
Safety Strategy at Pfizer and is based in New
York. She serves as a member of development
strategy teams and implements epidemiology
studies in support of development initiatives.
She is also responsible for authoring the epide-
miology sections of key safety documents. Prior
to joining Pfizer, she was Associate Director,
Global Clinical Epidemiology. Lisa has health
economics and outcomes research experience
from Bristol-Myers Squibb. Lisa received both
her PhD and MPH in Epidemiology from Colum-
bia University. She is currently Adjunct Assis-
tant Professor at Hunter College, City University
of New York. She is also invited faculty for the
Epidemiology and Population Health Summer
Institute at Columbia University.
Lisa Weiss, Ph.D., M.P.H.
Committee Member

6. Women In Science and Corporate Sponsor Volunteers
Director (Acting) Medical Countermeasures &
Emergency Preparedness/Operations—CDRH
at FDA
Suzanne is the Director (Acting) of Medical Counter-
measures and Emergency Preparedness/Operations in
the Office of the Center Director at the Center for De-
vices and Radiological Health (CDRH), US FDA. Suz-
anne joined FDA in October 2010. Initially recruited as
a Commissioner’s Fellow, she became a Medical Officer
in the Office of Device Evaluation (ODE), Division of
Surgical Orthopedic and Restorative Devices (DSORD),
Plastic and Reconstructive Surgery Branch (PRSB) in
August 2011. Suzanne brings subject matter expertise
in the management of burn injuries and complex skin
& soft tissue wounds to the Agency. She actively par-
ticipates in several inter-Agency working groups and
integrated program teams on behalf of FDA for the
Medical Counter Measures Initiative known as
PHEMCE, Public Health Emergency Medical Counter-
measures Enterprise for chemical, biological, radio-
logical and nuclear threats. Suzanne trained as a gen-
eral surgeon and then completed a combined clinical
and research burn fellowship at Cornell Medical Col-
lege - New York Hospital from 1991-1994. She recently
completed her Executive MBA studies at NYU-Stern
School of Business with a specialization in strategy and
leadership.
Suzanne Schwartz, M.D., MBA
Adjunct Committee Member
Scientist, Cellular Pharmacology, Merck
Seema is a Scientist in Cellular Pharmacology at
Merck She obtained a B.Sc. from Rutgers Univer-
sity in Anthropology, Psychology, Cell Biology and
Neuroscience, an M.Sc. from New York University
in Biology, and a graduate certificate in Pharma-
ceutical Management from Stevens Institute of
Technology. Seema has 10 years of scientific re-
search experience in the fields of Behavioral Phar-
macology, Molecular Neuroscience, and Oncology
Drug Discovery. She sat on the Junior Board of
Solving Kids’ Cancer, a non profit organization,
and was a Mentor in the Rutgers Women Invest-
ing In and Guiding Students (WINGS) program. In
addition to her work with Women In Science,
Seema was a Mentee in the 2010 HBA Metro
Chapter Group Mentoring Program. Seema is also
on Special Assignment with Merck's Global Mar-
ket Research & Analytics group. She is a student
at the Rutgers Business School working towards
her MBA.
Seema Tevar, M.Sc.
Adjunct Committee Member
Special Thanks & Gratitude to our Corporate Volunteers
at BMS
Barbara Christian
Eileen Grimes
Denise Papiernik
Vildan Kortan
Bahar Demirdirek
Paula Mastrangelo
Cassandra Koenig
Monica Adams